First-line lorlatinib treatment in a 19-year-old patient with ALK-rearranged pulmonary large-cell neuroendocrine carcinoma: a case report and literature review

医学 甲状腺癌 降钙素 病理 嗜铬粒蛋白A 甲状腺 内科学 肿瘤科 免疫组织化学
作者
Fatih Kemik,Pınar Bulutay,Cevat İlteriş Kıkılı,Bahadır Köylü,Nazan Demir,Elif Değırmencı,Kadir Burak Özer,Çisel Aydin Meriçöz,Serhan Tanju,Fatih Selçukbırıcık
出处
期刊:Anti-Cancer Drugs [Lippincott Williams & Wilkins]
卷期号:37 (1): 82-88 被引量:3
标识
DOI:10.1097/cad.0000000000001754
摘要

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive subtype of nonsmall cell lung cancer, typically occurring in elderly male smokers. Its occurrence in the adolescent population is exceptionally uncommon, with only a handful of cases reported in the literature. Even more rarely, LCNEC harbors ALK fusions, an unusual molecular alteration with important therapeutic relevance. We report a 19-year-old female patient who presented with bone pain and was found to have widespread skeletal and mediastinal lymph node involvement. Initial workup revealed elevated serum calcitonin and carcinoembryonic antigen (CEA) levels, and histopathology showed high-grade neuroendocrine carcinoma with immunoreactivity for chromogranin, synaptophysin, CD56, as well as calcitonin and CEA. Due to the neuroendocrine phenotype and calcitonin positivity, metastatic medullary thyroid carcinoma was initially suspected. However, thyroid fine needle aspiration from the suspicious thyroid nodule did not provide any evidence in this direction, and the RET mutation testing was also negative. Further molecular analysis revealed an EML4-ALK fusion and a TP53 mutation in tumor tissue. The patient was diagnosed with ALK-positive LCNEC and treated with lorlatinib and denosumab combination. A marked clinical and metabolic response was achieved within 3 months of treatment initiation. To our knowledge, this is the first reported case of ALK-rearranged pulmonary LCNEC in an adolescent patient treated with a tyrosine kinase inhibitor. This case underscores the extreme rarity of LCNEC in adolescents, highlighting that ALK rearrangements, although exceptionally rare in this histological subtype, can have significant therapeutic implications. It further emphasizes the importance of routine molecular profiling in atypical clinical scenarios and supports the utility of targeted therapies in rare tumor subsets.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
落梦发布了新的文献求助10
刚刚
ngyx发布了新的文献求助10
刚刚
晨曦发布了新的文献求助10
1秒前
runrun完成签到,获得积分10
1秒前
大个的应助被十二一字曾采纳,获得10
2秒前
天天快乐的应助被十二一字曾采纳,获得10
2秒前
周周发布了新的文献求助10
3秒前
4秒前
aaa完成签到,获得积分10
5秒前
科研通AI6.3的应助被zgxj采纳,获得10
5秒前
赘婿的应助被buqi采纳,获得50
5秒前
My_magnum_opus的应助被Seorina采纳,获得30
5秒前
6366336发布了新的文献求助10
6秒前
mmma发布了新的文献求助10
8秒前
9秒前
健忘不可完成签到,获得积分10
10秒前
10秒前
10秒前
机智铃铛关注了科研通微信公众号
11秒前
小蘑菇的应助被晨曦采纳,获得10
12秒前
Ava的应助被vy67采纳,获得10
12秒前
viviji完成签到,获得积分10
13秒前
kk完成签到,获得积分10
14秒前
小二郎的应助被愤怒的迎南采纳,获得10
16秒前
cdercder的应助被标致青雪采纳,获得10
16秒前
Tay完成签到 ,获得积分10
16秒前
华仔的应助被just do it采纳,获得10
16秒前
成就的德地完成签到,获得积分10
18秒前
赘婿的应助被水产里的遗传采纳,获得10
19秒前
19秒前
20秒前
20秒前
20秒前
英姑的应助被无私的画笔采纳,获得10
22秒前
幽默玉米完成签到,获得积分10
22秒前
科研通AI6.3的应助被master采纳,获得10
23秒前
暮晓见发布了新的文献求助10
23秒前
23秒前
24秒前
wen发布了新的文献求助50
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485